RxDoctor Payments Data

Kristan Higginbotham

Family · Marion, INNPI 1467715094

Payments from drug & device makers

$2,231in general payments, 2019–2025

Across 150 payments — averaging $14.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$891
  • Bayer$243
  • Novo Nordisk$211
  • Phathom Pharmaceuticals, Inc.$176
  • Lilly USA, LLC$152
  • Medtronic$136
  • plus $423 from 11 others

What the payments were for

  • Food & beverage$2,231100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,231 in reported general payments places this provider in the 80th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$46,551
Medicare patients
238
Services billed
471

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$38,753
EliquisApixaban16$17,122
MyrbetriqMirabegron17$11,133
JardianceEmpagliflozin11$9,888
Breo ElliptaFluticasone/Vilanterol17$8,507
LantusInsulin Glargine,hum.Rec.Anlog13$3,320
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$2,875
Tolterodine Tartrate ErTolterodine Tartrate12$1,471
PaxlovidNirmatrelvir/Ritonavir11$1,427
Albuterol Sulfate HfaAlbuterol Sulfate57$1,416
Atorvastatin Calcium179$1,339
Gabapentin90$1,310
Omeprazole121$1,015
Buspirone Hcl42$944
Fluticasone Propionate56$836

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$45$47,26054 claims
PfizerEliquis, Paxlovid$84$18,54927 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,392 family providers in Indiana.

Other family in Marion

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →